Placebo of Darolutamide — Competitive Intelligence Brief

Placebo of Darolutamide (Placebo of Darolutamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nonsteroidal antiandrogen. Area: Oncology.

phase 3 nonsteroidal antiandrogen androgen receptor Oncology Small molecule

Target snapshot

Placebo of Darolutamide (Placebo of Darolutamide) — Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie. Darolutamide is a nonsteroidal antiandrogen that competitively inhibits the action of androgens, such as testosterone and dihydrotestosterone, at their receptor sites in various tissues.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo of Darolutamide TARGET	Placebo of Darolutamide	Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie	phase 3	nonsteroidal antiandrogen	androgen receptor
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Nubeqa	darolutamide	Bayer	marketed		androgen receptor (AR)	2019-01-01
Erleada	apalutamide	Johnson & Johnson	marketed		Androgen receptor	2018-01-01
APALUTAMIDE	APALUTAMIDE		marketed		Androgen Receptor (AR)	2018-01-01
Aveed	TESTOSTERONE UNDECANOATE	Marius	marketed	Androgen	Androgen receptor	2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (nonsteroidal antiandrogen class)

1. Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie · 1 drug in this class